EP1702074A2 - Procedes permettant d'empecher l'incorporation d'acides amines non standard dans des proteines - Google Patents
Procedes permettant d'empecher l'incorporation d'acides amines non standard dans des proteinesInfo
- Publication number
- EP1702074A2 EP1702074A2 EP04817242A EP04817242A EP1702074A2 EP 1702074 A2 EP1702074 A2 EP 1702074A2 EP 04817242 A EP04817242 A EP 04817242A EP 04817242 A EP04817242 A EP 04817242A EP 1702074 A2 EP1702074 A2 EP 1702074A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dehydrogenase
- leucine
- protein
- norleucine
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 317
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 296
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 238
- 238000010348 incorporation Methods 0.000 title claims abstract description 68
- 230000002265 prevention Effects 0.000 title description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims abstract description 273
- 230000000593 degrading effect Effects 0.000 claims abstract description 84
- 102000016901 Glutamate dehydrogenase Human genes 0.000 claims abstract description 78
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 73
- 101710100604 Valine dehydrogenase Proteins 0.000 claims abstract description 59
- 108010028658 Leucine Dehydrogenase Proteins 0.000 claims abstract description 46
- 229930195712 glutamate Natural products 0.000 claims abstract description 31
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 30
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 claims abstract description 28
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940029872 leucine / phenylalanine Drugs 0.000 claims abstract description 27
- MBZXSJWDBIIBLL-GDVGLLTNSA-N Homoisoleucine Chemical compound CCC(C)C[C@H](N)C(O)=O MBZXSJWDBIIBLL-GDVGLLTNSA-N 0.000 claims abstract description 19
- KWSUGULOZFMUDH-RITPCOANSA-N (2s,3r)-2-amino-3-methylhexanoic acid Chemical compound CCC[C@@H](C)[C@H](N)C(O)=O KWSUGULOZFMUDH-RITPCOANSA-N 0.000 claims abstract description 16
- 108010078226 phenylalanine oxidase Proteins 0.000 claims abstract description 14
- 108030002156 Opine dehydrogenases Proteins 0.000 claims abstract description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 5
- 241000588724 Escherichia coli Species 0.000 claims description 95
- 102000004190 Enzymes Human genes 0.000 claims description 57
- 108090000790 Enzymes Proteins 0.000 claims description 57
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 38
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 36
- 108010006025 bovine growth hormone Proteins 0.000 claims description 31
- 244000005700 microbiome Species 0.000 claims description 24
- 108020004414 DNA Proteins 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 239000004472 Lysine Substances 0.000 claims description 12
- 108010051696 Growth Hormone Proteins 0.000 claims description 10
- 102000018997 Growth Hormone Human genes 0.000 claims description 10
- 108020004511 Recombinant DNA Proteins 0.000 claims description 9
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 241000193755 Bacillus cereus Species 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 6
- 241000605121 Nitrosomonas europaea Species 0.000 claims description 6
- 241001223867 Shewanella oneidensis Species 0.000 claims description 6
- 241001468227 Streptomyces avermitilis Species 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 241000192673 Nostoc sp. Species 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 241000282465 Canis Species 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000282324 Felis Species 0.000 claims description 2
- 241000937894 Nostoc sp. A Species 0.000 claims 3
- 230000014509 gene expression Effects 0.000 abstract description 59
- 230000004186 co-expression Effects 0.000 abstract description 34
- 230000002829 reductive effect Effects 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 5
- 230000008030 elimination Effects 0.000 abstract description 3
- 238000003379 elimination reaction Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 257
- 235000001014 amino acid Nutrition 0.000 description 219
- 229940024606 amino acid Drugs 0.000 description 217
- 210000004027 cell Anatomy 0.000 description 73
- 229930182817 methionine Natural products 0.000 description 59
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 57
- 239000013612 plasmid Substances 0.000 description 21
- 239000001963 growth medium Substances 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 15
- 238000006731 degradation reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 12
- 229960000310 isoleucine Drugs 0.000 description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 12
- 238000013459 approach Methods 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 102000003929 Transaminases Human genes 0.000 description 8
- 108090000340 Transaminases Proteins 0.000 description 8
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 238000007833 oxidative deamination reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108700023156 Glutamate dehydrogenases Proteins 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 108090000854 Oxidoreductases Proteins 0.000 description 6
- 108030006586 Phenylalanine dehydrogenases Proteins 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 101150025049 leuB gene Proteins 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108020004566 Transfer RNA Proteins 0.000 description 5
- 230000001851 biosynthetic effect Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 101150095957 ilvA gene Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- XNIHZNNZJHYHLC-UHFFFAOYSA-N 2-oxohexanoic acid Chemical compound CCCCC(=O)C(O)=O XNIHZNNZJHYHLC-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108020005199 Dehydrogenases Proteins 0.000 description 4
- 241001646716 Escherichia coli K-12 Species 0.000 description 4
- 102000004867 Hydro-Lyases Human genes 0.000 description 4
- 108090001042 Hydro-Lyases Proteins 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 4
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- -1 norleucine) Chemical class 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010031025 Alanine Dehydrogenase Proteins 0.000 description 3
- 108010036684 Glycine Dehydrogenase Proteins 0.000 description 3
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 3
- 101000739876 Homo sapiens Brain-derived neurotrophic factor Proteins 0.000 description 3
- 101100123410 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) hacA gene Proteins 0.000 description 3
- 101100123415 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) hacB1 gene Proteins 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 101100181662 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) leuC1 gene Proteins 0.000 description 3
- 101100288829 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) leuD1 gene Proteins 0.000 description 3
- 241000607715 Serratia marcescens Species 0.000 description 3
- 241000203775 Thermoactinomyces Species 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000005550 amino acid supplement Nutrition 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 102000051542 human BDNF Human genes 0.000 description 3
- 229940077456 human brain-derived neurotrophic factor Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 101150087199 leuA gene Proteins 0.000 description 3
- 101150081723 leuC gene Proteins 0.000 description 3
- 101150019665 leuD gene Proteins 0.000 description 3
- WQVJUBFKFCDYDQ-BBWFWOEESA-N leubethanol Natural products C1=C(C)C=C2[C@H]([C@H](CCC=C(C)C)C)CC[C@@H](C)C2=C1O WQVJUBFKFCDYDQ-BBWFWOEESA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 101100277699 Clostridium symbiosum gdh gene Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 2
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 108010074124 Escherichia coli Proteins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 2
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 241000221961 Neurospora crassa Species 0.000 description 2
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000187434 Streptomyces cinnamonensis Species 0.000 description 2
- 241000187438 Streptomyces fradiae Species 0.000 description 2
- 241000203773 Thermoactinomyces intermedius Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000193450 [Clostridium] symbiosum Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000002642 cobra venom Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 101150019455 gdh gene Proteins 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 102000049953 human LEP Human genes 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000754 repressing effect Effects 0.000 description 2
- 239000007320 rich medium Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 229940005605 valeric acid Drugs 0.000 description 2
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- ONFOSYPQQXJWGS-UHFFFAOYSA-N 2-hydroxy-4-(methylthio)butanoic acid Chemical compound CSCCC(O)C(O)=O ONFOSYPQQXJWGS-UHFFFAOYSA-N 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-M 2-oxobutanoate Chemical compound CCC(=O)C([O-])=O TYEYBOSBBBHJIV-UHFFFAOYSA-M 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- FHSUFDYFOHSYHI-UHFFFAOYSA-N 3-oxopentanoic acid Chemical compound CCC(=O)CC(O)=O FHSUFDYFOHSYHI-UHFFFAOYSA-N 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000186073 Arthrobacter sp. Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000193408 Bacillus badius Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014429 Insulin-like growth factor Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102220537074 NKG2-C type II integral membrane protein_K89L_mutation Human genes 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000489455 Sitta europaea Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010006873 Threonine Dehydratase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 229940067621 aminobutyrate Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035071 co-translational protein modification Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010060845 lactose permease Proteins 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
- C12N9/0016—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with NAD or NADP as acceptor (1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Definitions
- the invention relates to the preparation of heterologous proteins from microorganisms and, more specifically, to preventing or substantially eliminating the incorporation of norleucine or other non-standard amino acids into these recombinant heterologous proteins.
- the present invention provides the compositions and methods necessary to prevent the incorporation of norleucine or other non-standard amino acids into these heterologous proteins.
- Norleucine is an analog of the amino acid methionine that can be misincorporated into a protein in the place of methionine.
- Escherichia coli E. coli
- norleucine can be biosynthesized by the enzymes of the leucine biosynthetic pathway.
- E. coli Escherichia coli
- Many heterologous proteins have norleucine mistakenly incorporated in places methionine residues should appear.
- the misincorporation of norleucine is undesirable because it usually results in the production of an altered protein, having less than optimal characteristics.
- norleucine is an analog of methionine (Harris and Kohn, 1941; Rowley, 1953; Adelberg, 1958; Rowbury, 1965; Karlstrom, 1965).
- norleucine is inhibitory to a variety of species of bacteria.
- Dittmer (1950) noted that norleucine is a structural analog of methionine by virtue of the fact that when the sulfur atom in methionine is replaced by a methylene group norleucine is the result (see Figure 1).
- norleucine was recognized to be an amino acid antagonist, and a structural analog, of methionine.
- Norleucine attracted significantly more interest than most amino acid analogs, since it was so well characterized and readily available — aspects stemming from the time when norleucine was thought to be a standard protein amino acid.
- norleucine was a structural analog of methionine that could be incorporated into protein by mis-charged methionine-tRNA. Furthermore, it was clear that a sufficient amount of available methionine inhibited the incorporation of norleucine into protein by out-competing norleucine for the charging of methionine-tRNA. Finally, it was known that norleucine was a naturally occurring amino acid, synthesized in bacteria by the enzymes of the leucine biosynthetic pathway.
- norleucine is not a standard protein amino acid, it is desirable to minimize its incorporation into proteins in order to produce products that are as "natural” as possible (i.e. contain only the amino acids encoded by the DNA sequence).
- Previously devised methods for reducing the incorporation of norleucine into protein were based on the prior art describing the biosynthesis of norleucine and the incorporation of norleucine into protein. That is, the prior art indicated that the biosynthesis of norleucine could be reduced by supplementation of the culture medium with leucine, thereby repressing the enzymes of leucine (and norleucine) biosynthesis.
- Brunner et al. in the '690 patent, and by Brunner et al., in U.S. Pat. No. 5,698,418.
- Brunner et al. in the '418 patent, also provide a description of a means for reducing norleucine incorporation into protein by supplementing the growth medium with other amino acids, specifically, leucine or cysteine. All of these approaches have the disadvantage of requiring the supplementation of the culture medium with one or more amino acids.
- Another approach for preventing norleucine incorporation is to mutate the protein-encoding gene at the codons originally encoding methionine so that they encode other amino acids.
- This approach has the disadvantage of altering the primary (and perhaps secondary and tertiary) structure of the protein, which may result in significant and undesirable changes in the biological properties, activity, and usefulness of the protein.
- Norvaline another non-standard amino acid, is biosynthesized by the same pathway responsible for the synthesis of norleucine (see, Kisumi, et al. (1976) and Bogosian et al. (1989)).
- the instant invention meets this need for an efficient and inexpensive means of preventing the incorporation of norleucine and/or other non-standard amino acids into heterologous proteins.
- the instant invention meets this need by providing the methods and compositions necessary to prevent or substantially inhibit the incorporation of norleucine and/or other non-standard amino acids into heterologous proteins, without the necessity of supplementing the growth medium with amino acids or altering the protein's amino acid sequence to eliminate methionine or other naturally occurring amino acids.
- the present invention meets this need by providing a method of reducing the incorporation of norleucine and/or other non-standard amino acids into proteins by degrading the norleucine and/or non-standard amino acids that the cell biosynthesizes.
- An important aspect of this invention is that it provides a means for achieving a reduction or elimination of the incorporation of norleucine and/or other non-standard amino acids into proteins without necessitating the supplementation of the culture medium with any amino acids.
- Other enzymes that might degrade norleucine, norvaline, beta-methylnorleucine, and/or homoisoleucine (and/or other non-standard amino acids) include: other amino acid dehydrogenases, such as alanine dehydrogenase, glycine dehydrogenase, and opine dehydrogenase; aminotransferases (also known as transaminases); amino acid dehydratases; and various amino acid oxidases. It is noted that the list of enzymes, supra, especially those in Tables 1 and 2, is provided by way of example only, and is not exclusive.
- the instant invention provides for methods for preparing recombinant strains of bacteria (e.g., E. coli) with co-expression or enhanced expression of glutamate dehydrogenases, leucine dehydrogenases, phenylalanine dehydrogenases, valine dehydrogenases, glutamate/leucine/phenylalanine/valine dehydrogenases, opine dehydrogenases, other amino acid dehydrogenases, and other enzymes such as aminotransferases (also known as transaminases), amino acid dehydratases, and various amino acid oxidases, exhibiting activity for the degradation of norleucine and/or other non-standard amino acids, including norvaline, homoisoleucine, and beta-methylnorleucine.
- the instant invention provides for variants of these enzymes exhibiting increased activity for the degradation of norleucine and/or other non-standard amino acids, including norvaline, homoisoleucine, and beta-methylnorleucine
- Glutamate dehydrogenase is an enzyme that degrades the amino acid glutamate via oxidative deamination to form 2-ketoglutarate and ammonia (see Figure 1).
- GDH from the organism Clostridium symbiosum has been crystallized and studied extensively.
- a variant form of the Clostridium symbiosum GDH has been identified, in which the lysine residue at position 89 has been changed to a leucine residue (this is referred to as the K89L form of GDH).
- GDH glutamate dehydrogenase
- the instant invention provides for recombinant DNA molecules encoding the GDH proteins described as well as the recombinant proteins encoded.
- the instant invention also provides for methods for preparing recombinant strains of bacteria (e.g., E. coli) with enhanced expression of the wild-type GDH gene and/or enhanced expression of the K92L variant form of E. coli GDH.
- the instant invention also provides for methods for preparing recombinant strains of bacteria (e.g., E. coli) with co- expression or enhanced expression of leucine dehydrogenases, valine dehydrogenases, and glutamate/leucine/phenylalanine/valine dehydrogenases.
- the modified cell has co-expression or enhanced expression of the norleucine degrading enzyme as compared with its expression in the unmodified cell.
- Various embodiments of the instant invention provide new protein expression systems in which heterologous proteins can be produced, where these proteins have a reduced or substantially eliminated norleucine content, and yet the bacteria are grown on a minimal medium; and, thus, do not require supplementation with any amino acids whatsoever (nevertheless, supplemental amino acids may be added). Also provided are the bacterial strains so produced.
- the instant invention also provides various means for reducing the incorporation of norleucine and/or other non-standard amino acids into heterologous proteins without the use of expensive amino acid supplements. That is, the methods of the instant invention do not require provision of exogenous amino acids (such as leucine, methionine, valine, or isoleucine) to compensate for the inhibition of a amino acid biosynthetic pathway, nor excessive methionine required in order to competitively inhibit the incorporation of norleucine or other non-standard amino acids into proteins.
- exogenous amino acids such as leucine, methionine, valine, or isoleucine
- the instant invention provides methods and compositions that prevent or substantially eliminate the incorporation of norleucine and/or other non-standard amino acids into heterologous proteins by engineering a cell so that it degrades most or all of the norleucine, and/or other non-standard amino acids, that it synthesizes.
- the prevention of the incorporation of norleucine and/or other non-standard amino acids into a heterologous protein is accomplished by co-expressing the heterologous protein in a cell with co-expression or enhanced expression of a protein, or enzymatically functional portion of a protein, that degrades norleucine and/or other non-standard amino acids.
- the various aspects of this embodiment provide for a microorganism co-expressing at least one heterologous protein and at least one non-standard amino acid degrading protein (or enzymatically active portion thereof).
- Figure 1 Shows the basic structures for the indicated amino acids (methionine, norleucine, leucine, and glutamate). Also shown are the results of oxidative deamination of norleucine and glutamate, respectively.
- Figure 2A-2B Show the structures for the indicated amino acids: methionine, norleucine, norvaline, and leucine (Fig. 2A); homoisoleucine, isoleucine, valine, and beta- methylnorleucine (Fig. 2B). DESCRIPTION OF THE SEQUENCE LISTINGS
- heterologous protein(s) preferably refers to a protein that is not expressed in the organism in an untransformed state. Put another way, it means that the protein is not native to the organism.
- heterologous protein does not encompass any protein that is typically or routinely used as a "marker” (meaning a selection marker). Such “markers” include, but are not limited to antibiotic resistance genes and proteins capable of processing substrate so as to provide a colored product for a colorimetric assay.
- co-express proteins/DNA molecules which are expressed in a cell as a result of a recombinant event. That is, at least one of the following is true: either the DNA and/or protein is expressed from an extra genomic vector (such as a plasmid) that has been introduced into the cell via a molecular biological technique; and/or the DN A/protein is expressed from a location in the cell's genome other than where the DNA sequence naturally occurs.
- an extra genomic vector such as a plasmid
- co-expression refers to the modification of a cell so that the expression of a particular RNA transcript or protein is increased in that modified cell as compared with the level of expression of that same RNA or protein in an unmodified cell.
- Means for co-expression or enhanced expression contemplated as being part of the instant invention include, but are not limited to: expression of the gene from an extra- genomic DNA molecule (e.g. a plasmid); expression of the gene from a non-native location in the cellular genome; and/or expression of the gene from its native genomic location, but with modification of the gene's normal regulatory control system so as to stimulate expression or reduce suppression (that is any modification which increases the gene's expression).
- co-expressing refers to at least two distinct phenomena.
- One aspect of co-expression or enhanced expression is the increased expression of a gene sequence already present in the cell (e.g. the increased expression, in E. coli, of RNA and/or protein that is native to E. coli, such as E. coli glutamate dehydrogenase) so that the RNA and/or protein encoded by the native sequence is present at higher levels than in the non-modified cell.
- a second aspect of co-expression or enhanced expression is the expression of a "new" sequence that is not native to the cell.
- RNA and/or protein in a microorganism at a level that is greater than the level, of that same RNA and/or protein, expressed by the same microorganism in its unmodified form (i.e. a microorganism that is not "co-expressing" the RNA and/or protein).
- non-standard amino acid degrading enzyme and/or non-standard amino acid degrading protein
- non-standard amino acid degrading protein preferably refer to enzymes and/or proteins, or catalytically active fragments thereof, that degrade one or more of the non-standard amino acids; these nonstandard amino acids including, but not limited to: norleucine, norvaline, beta- methylnorleucine, and homoisoleucine.
- Non-standard amino acid degrading proteins include, but are not limited to, all of those proteins specifically described herein (and/or listed in any of the tables herein) as being capable of degrading one or more non-standard amino acids.
- proteins structurally related to those specifically described proteins (e.g. see Table 4).
- proteins include the protein super-family comprising: glutamate dehydrogenases, leucine dehydrogenases, valine dehydrogenases, phenylalanine dehydrogenases, glutamate/leucine/phenylalanine/valine dehydrogenases, and opine dehydrogenases.
- non-standard amino acids preferably refers to one or more amino acids that are not among the 20 amino acids most commonly found in proteins produced by living organisms.
- the "standard” amino acids are: 1) alanine, 2) arginine 3) asparagine, 4) aspartate, 5) cysteine, 6) glutamate, 7) glutamine, 8) glycine, 9) histidine, 10) isoleucine, 11) leucine, 12) lysine, 13) methionine, 14) phenylalanine, 15), proline, 16) serine, 17) threonine, 18) tryptophan, 19) tyrosine, and 20) valine.
- Non-standard amino acids include, but are not limited to, norleucine, norvaline, beta- methylnorleucine, and homoisoleucine.
- the term "substantially eliminates" as it pertains to the presence of norleucine or other non-standard amino acids in proteins preferably means that there is no norleucine or other non-standard amino acids present in the proteins or that their presence is so low that it is below the limits of detection.
- the instant invention provides for compositions and methods useful to prevent or substantially eliminate the incorporation of one or more non-standard amino acids (including, but not limited to: norleucine, norvaline, beta-methylnorleucine, and/or homoisoleucine) into heterologous proteins.
- Various embodiments of the instant invention provide for methods that prevent incorporation of norleucine, norvaline and/or the other non-standard amino acids into proteins that are heterologously expressed.
- the incorporation of norleucine and/or other non-standard amino acids into heterologous proteins is prevented or substantially eliminated by co-expression of the heterologous protein in a cell with co-expression or enhanced expression of at least one enzyme/protein (or a catalytically active fraction thereof) that catalyzes the degradation of norleucine and/or one or more other non-standard amino acids. That is, the instant invention provide for microorganisms co-expressing at least one heterologous protein and at least one non- standard amino acid degrading protein.
- the norleucine or other non-standard amino acid degrading protein is a glutamate dehydrogenase (GDH).
- GDH glutamate dehydrogenase
- the norleucine or other non-standard amino acid degrading enzyme is GDH from Escherichia coli (E. coli).
- the norleucine or other non-standard amino acid degrading protein comprises a lysine 92 to leucine (K92L) variant of E. coli GDH.
- the heterologous protein is co-expressed in E. coli with enhanced expression of either an native E.
- the norleucine or other non-standard amino acid degrading protein comprises a leucine dehydrogenase, or a valine dehydrogenase, or a glutamate/ leucine/phenylalanine/valine dehydrogenase.
- the modified cell has co-expression or enhanced expression of the norleucine or other non-standard amino acid degrading protein as compared with the protein's expression in the non-modified cell.
- the GDH K92L variant may further comprise other variations from the native sequence. All such variants are considered to be part of the instant invention so long as they do not diminish the protein's ability to degrade norleucine or other non-standard amino acids to a degree where it is no longer useful according to the instant invention.
- the non-standard amino acid degrading protein may be selected from any protein found to produce a suitable degree of degradation of norleucine and/or other non-standard amino acids.
- other proteins provided for use according to the instant invention include, but are not limited to, phenylalanine dehydrogenase (examples of such a phenylalanine dehydrogenases are shown in Tables 1 and 2, supra, and Table 4, infra.
- leucine and valine dehydrogenases include, but are not limited to those obtained from Streptomyces, Thermoactinomyces, Clostridium, Bacillus, and Corynebacterium, see also the examples listed in Tables 1 and 2, supra), and other amino acid dehydrogenases, such as glutamate/leucine/phenylalanine/valine dehydrogenase, alanine dehydrogenase, glycine dehydrogenase, and opine dehydrogenase; aminotransferases (also known as transaminases); amino acid dehydratases; and various amino acid oxidases.
- the non-standard amino acid degrading enzymes are selected from the group consisting of: glutamate dehydrogenases, leucine dehydrogenases, valine dehydrogenases glutamate/leucine/phenylalanine/valine dehydrogenases, phenylalanine dehydrogenases, and opine dehydrogenases.
- the non-standard amino acid to be degraded is selected from one or more of the group consisting of norleucine, norvaline, beta- methylnorleucine, and homoisoleucine and the non-standard amino acid degrading enzyme is selected from one or more of the following: a glutamate dehydrogenase, a phenylalanine dehydrogenase, a leucine dehydrogenase, a valine dehydrogenase, a glutamate/ leucine/phenylalanine/valine dehydrogenase and an opine dehydrogenase (nevertheless these lists are not exclusive).
- the non-standard amino acid degrading enzyme degrades norleucine and/or other non-standard amino acids and is encoded by a DNA molecule comprising a sequence as provided in SEQ DD NO:l, 3, 5, 7, 9, 11, 13, or 15.
- the norleucine and/or other non-standard amino acid degrading enzyme has a peptide sequence comprising the sequence of SEQ RO NO:2, 4, 6, 8, 10, 12, 14, orl6.
- the heterologous protein is any protein or protein fragment of interest that can be advantageously expressed in bacteria.
- the heterologous protein is a somatotropin.
- the somatotropin is a human, bovine, equine, porcine, ovine, canine, or feline somatotropin.
- the heterologous protein is bovine somatotropin (bST).
- heterologous proteins to which the instant invention is drawn include, but are not limited to human interleukin-2, recombinant human insulin-like growth factor, human growth factor, human macrophage colony stimulating factor (M-CSF), human leptin, and human brain- derived neurotrophic factor. These proteins are exemplary only, the list is not exclusive. Accordingly, any heterologous protein for which the exclusion of norleucine and/or one or more other non-standard amino acids is desired or necessary, may advantageously be produced in accordance with the instantly described invention.
- Proteins that are contemplated as being part of this group of "marker peptides” include all proteins commonly used by those of ordinary skill in the art as a means of identifying cells that have been transformed. This list includes, but is not limited to antibiotic resistance genes such as ampicillin resistance genes, chloramphenicol acetyl transferase (CAT), tetracycline resistance, kanamycin resistance, neomycin resistance, streptomycin resistance, spectinomycin resistance, gentamicin resistance, and zeocin resistance. This list also includes proteins that are essential for the maintenance of the plasmid, such as proteins involved in plasmid DNA replication, regulation of plasmid copy number, and plasmid mobilization and transfer. This list also includes proteins used to select for the presence of plasmid inserts, such as positive selection markers.
- antibiotic resistance genes such as ampicillin resistance genes, chloramphenicol acetyl transferase (CAT), tetracycline resistance, kanamycin resistance, neo
- heterologous protein is a bovine somatotropin that is to be isolated for use in cattle or another susceptible animal. It is typically important that a heterologous peptide be of its native sequence (or as close thereto as possible) when it is to be used in a higher organism, such as a mammal. For these uses, proteins having minimal norleucine and/or other non-standard amino acid content are most desirable. Similarly, for this reason it is also desirable to express proteins having their native sequence (i.e. not mutated to replace codons for methionine or other standard amino acids with codons encoding a different amino acid, in an effort to prevent incorporation of norleucine and/or other non-standard amino acids).
- Various embodiments of the invention provide for the co-expression of any desired heterologous protein in a cell with co-expression or enhanced expression of one or more norleucine and/or other non-standard amino acids degrading proteins (or enzymatically active fragments thereof).
- bovine somatotropin (bST) or any other type of somatotropin (ST) can be co-expressed in a cell with enhanced expression of wild-type E. coli GDH (or with enhanced expression of the K92L E. coli GDH variant).
- a desired heterologous protein can be co-expressed in a cell modified to have co-expression or enhanced expression of any other norleucine and/or other non-standard amino acid degrading protein or a catalytically active fragment of any such protein.
- one particularly preferred embodiment of the instant invention provides for bST, or another somatotropin, being co-expressed in E. coli with enhanced expression of E. coli GDH or enhanced expression of a K92L variant of E. coli GDH.
- the E. coli strain may be a K-12 strain or any other strain suitable for protein expression.
- the methods of the instant invention may be carried out using any desired combination of norleucine and/or other non-standard amino acids degrading protein, heterologous protein, and host cell. That is, the invention is not limited to any particular combinations of cell, norleucine and/or other non-standard amino acids degrading protein, and heterologous protein. Rather, all possible combinations and/or permutations of the cells, norleucine and/or other non-standard amino acids degrading proteins, and heterologous proteins described herein are envisioned as being part of the instant invention.
- Various embodiments of the instant invention also provide for methods of producing and/or isolating proteins wherein the percent of proteins comprising norleucine and/or other non- standard amino acids has been reduced by at least 50% (as compared with the level of heterologous protein comprising norleucine and/or other non-standard amino acid(s), when the heterologous protein is produced in the same cell type and under the same conditions, except that the cell does not have co-expression or enhanced expression of a norleucine and/or other non- standard amino acid degrading protein).
- the percent reduction in norleucine and/or or other non-standard amino acid content is 60%, 70%, 80%, 90%, 95, 96, 97, 98, 99, or greater than 99%, and includes substantially 100% (i.e., no detectable non-standard amino acid). That is, in any embodiment of the invention, the percentage of heterologous protein comprising norleucine, and/or one or more other non-standard amino acids, is substantially zero.
- the percent reduction in norleucine (and/or other non-standard amino acid) content is typically calculated as a reduction in percentage of proteins containing norleucine (and/or other non-standard amino acid).
- any suitable method for analyzing the reduction in norleucine (and/or other non-standard amino acid) content may be used, such as calculating the amount of norleucine (and/or other non-standard amino acid) present in heterologous proteins isolated from cells that do not have co-expression or enhanced expression of a norleucine (and/or other non-standard amino acid) degrading protein and then comparing this result with the amount of norleucine (and/or other non-standard amino acid) in heterologous proteins present in heterologous proteins isolated from cells grown under identical conditions, except that the cells have co-expression or enhanced expression of a norleucine (and/or other non-standard amino acid) degrading protein.
- Other embodiments of the instant invention provide for methods of producing cells that have co-expression or enhanced expression of a norleucine (and/or other non-standard amino acid) degrading protein wherein the cells have a decreased pool of norleucine (and/or other non-standard amino acids), as compared with the same cells that do not express the norleucine (and/or other non-standard amino acid) degrading protein, when grown under conditions that are suitable to elicit norleucine (and/or other non-standard amino acid) production.
- the amount of norleucine and/or other non-standard amino acids present in the cells' amino acid pool is decreased by at least 20%.
- the amount of norleucine and/or other non-standard amino acids present in the amino acid pools of the cells is decreased by 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%o, 98%, 99%, greater than 99% or substantially 100%.
- Another method of measuring the reduction in amount of norleucine present is as a function of an increased ratio of methionine to norleucine (or, more generally, the ratio of the standard amino acid to the non-standard amino acid that can replace it, examples include, but are not limited to: the ratio of leucine to norvaline or methionine to norvaline and the ratio of isoleucine to homoisoleucine or isoleucine to homoisoleucine).
- the methionine to norleucine (or standard amino acid to non- standard amino acid) ratio is preferably increased to at least 1.2:1, more preferably the ratio is increased to 1.3:1, 1.4:1, 1.5:1, 1.6:1, 1.7:1, 1.8:1, or 1.9:1. More preferably the ratio is at least 2.0:1. Even more preferably, the ratio is greater than 2.0: 1.
- the cell may be of any type suitable for expression of a heterologous protein with simultaneously co-expression or enhanced expression of a norleucine (and/or other non-standard amino acid) degrading protein.
- the cell is from an organism that synthesizes norleucine (and/or one or more other non-standard amino acids) and incorporates such into heterologous protein.
- the cell expresses the norleucine (and/or other non-standard amino acid) degrading protein at a higher rate than the norleucine (and/or other non-standard amino acid) degrading protein is expressed in the native (non-transformed) cell.
- the cell is an E.
- the reduction in the content of the norleucine (and/or other non-standard amino acids) in heterologous proteins or reduction in norleucine (and/or other non-standard amino acids) content in the amino acid pool of the cell is accomplished by the co-expression or enhanced expression of one or more norleucine (and/or other non-standard amino acid) degrading proteins in the cell, in accordance with the methods described herein.
- Such co-expression or enhanced expression may be from an extra-genomic vector such as a plasmid or it may be from a genomic sequence that is not native to the cell, including expression from a non-native gene that has been integrated into the chromosome of the host cell, or it may result from a modification of the norleucine (and/or other non-standard amino acid) degrading protein's native regulatory control mechanism.
- the present invention envisions that the various aspects of the invention may be used in any combination with any of the other aspects described herein. Accordingly, the aspects of this embodiment of the invention include the co-expression of any heterologous protein with any suitable norleucine (and/or other non-standard amino acid) degrading protein in any suitable cell type.
- a norleucine (and/or other non-standard amino acid) degrading protein selected from one or more of the following: a glutamate dehydrogenase, a phenylalanine dehydrogenase, a valine dehydrogenase, a leucine dehydrogenase, a glutamate/leucine/phenylalanine/valine dehydrogenase, and an opine dehydrogenase; other amino acid dehydrogenases, such as alanine dehydrogenase and glycine dehydrogenase; aminotransferases (also known as transaminases); amino acid dehydratases; and various amino acid oxidases. Also contemplated by the instant invention is the use of catalytically active fragments or catalytically active variants of
- the norleucine (and/or other non-standard amino acid) degrading protein is a glutamate dehydrogenase, a leucine dehydrogenase, a valine dehydrogenase, or a glutamate/leucine/phenylalanine/valine dehydrogenase.
- the norleucine (and/or other non-standard amino acid) degrading protein is E. coli glutamate dehydrogenase or a lysine 92 leucine variant of E. coli glutamate dehydrogenase.
- the glutamate dehydrogenase comprises the amino acid sequence of SEQ IN NO:2 or SEQ DD NO:4. More preferably, the glutamate dehydrogenase is encoded by a DNA molecule comprising the sequence of SEQ ID NO:l or SEQ ID NO:3.
- the norleucine (and/or other non-standard amino acid) degrading protein is comprises a leucine hydrogenase having an amino acid sequence of SEQ ID NO:6, SEQ TD NO:8, SEQ ID NO: 10, or SEQ ID NO: 12; or a valine dehydrogenase having the amino acid sequence of SEQ ID NO: 14; or a glutamate/leucine/phenylalanine/valine dehydrogenase having an amino acid sequence of SEQ ID NO: 16.
- the leucine dehydrogenase is encoded by a DNA molecule comprising the sequence of SEQ ID NO:5, SEQ ID NO:7, SEQ ED NO:9, or SEQ DD NO:ll; or the valine dehydrogenase is encoded by a DNA molecule having the sequence of SEQ ID NO: 13; or the glutamate/leucine/phenylalanine/valine dehydrogenase is encoded by a DNA molecule having the sequence of SEQ DD NO: 15.
- heterologous proteins and norleucine (and/or other non-standard amino acid) degrading protein or fragments thereof
- vectors transformed into a host cell such as E. coli
- the heterologous protein and norleucine (and/or other non-standard amino acid) degrading protein are expressed from separate plasmids/vectors. In other embodiments they may be expressed from separate portions of the same plasmid or vector.
- one or both of the heterologous protein and norleucine (and/or other non-standard amino acid) degrading protein may be expressed from a site that is integral with the host cell's genome.
- the expression of the heterologous protein and the co-expression or enhanced expression of the norleucine (and/or other non-standard amino acid) degrading protein may be expressed from either constitutive or from inducible promoters.
- Many constitutive and inducible promoters are well characterized and known to those skilled in the art.
- the methods are effective to reduce the percentage of heterologous protein containing norleucine (and/or one or more other non-standard amino acids) to below 5%.
- the percentage of heterologous proteins containing norleucine (and/or other non-standard amino acid) is decreased to 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.01%, 0.05% and 0% or substantially 0% (meaning.that the level of non-standard amino acids is below detectable limits).
- the present invention also provides for the simultaneous expression of a heterologous protein with two or more norleucine (and/or other non-standard amino acid) degrading proteins each of which has co-expression or enhanced expression.
- bST can be simultaneously expressed with both wild-type and K92L variant E. coli GDH, if desired.
- the instant invention also provides for a recombinant E. coli glutamate dehydrogenase protein wherein amino acid residue 92 has been changed from the native lysine to a leucine.
- the recombinant GDH protein comprises the sequence of S ⁇ Q DD NO:4.
- the GDH protein consists of or consists essentially of the sequence of S ⁇ Q DD NO:4.
- the instant invention provides for cells comprising the recombinant E. coli GDH comprising the K92L variant.
- the cells are E. coli cells.
- the cells are E. coli K-12 cells.
- the instant invention is drawn to any cell containing the variant K92L GDH protein, such that it has an enhanced capacity to degrade norleucine.
- the invention also provides for a recombinant DNA capable of encoding the K92L variant of the E. coli GDH protein (or catalytically active fragment thereof).
- a preferred aspect of this embodiment provides for a recombinant DNA molecule comprising the sequence provided as S ⁇ Q DD NO:3.
- E. coli K92L GDH variants that further comprise variations at other amino acid residues.
- These variations are contemplated as being part of the instant invention so long as they do not reduce the ability of the encoded protein to degrade norleucine to a degree that makes it unsuitable for use to prevent or substantially eliminate norleucine incorporation into a heterologous protein expressed in a cell.
- various embodiments of the instant invention provide for norleucine (and/or other non-standard amino acid) degrading proteins that have been modified from their native primary structure (e.g., the CS2 mutant of the phenylalanine dehydrogenase from Thermoactinomyces intermedius (Kataoka et al, 1993)), but that still actively degrade non-standard amino acids, at rates that less than, equal to, or greater than the rates of the native protein.
- native primary structure e.g., the CS2 mutant of the phenylalanine dehydrogenase from Thermoactinomyces intermedius (Kataoka et al, 1993)
- Yet other aspects of this embodiment of the invention provide for DNA sequence encoding any of the proteins provided in the Examples, including, but not limited to leucine dehydrogenase from Bacillus cereus, Bacillus subtilis, Nostoc sp., or Shewanella oneidensis; valine dehydrogenase from Streptomyces avermitilis, and glutamate/leucine/phenylalanine/valine dehydrogenase from Nitrosomonas europaea.
- a cell comprising any one or more of the recombinant DNA molecules described herein.
- the cell is an E. coli cell.
- the cell is an E. coli K-12 cell.
- Other embodiments provide for cells comprising any of the recombinant DNA molecules described herein wherein co-expression or enhanced expression of a norleucine degrading protein prevents or substantially eliminates incorporation of norleucine into a heterologous protein co-expressed in the cell.
- inventions of the instant invention provide for methods of producing a protein in and/or isolating a protein from a cell or microorganism.
- the various embodiments of these methods comprise the use of any combination of the cells, heterologous proteins, and norleucine (and/or other non-standard amino acid) degrading proteins described herein.
- the various aspects of this embodiment comprise co-expressing a heterologous protein and in a cell or microorganism with co-expression or enhanced expression of a norleucine (and/or other non- standard amino acid) degrading protein and then isolating protein from the microorganism.
- the heterologous protein is isolated from the cell or microorganism.
- Example 1 Construction of plasmids co-expressing bovine somatotropin and either the wild-type or K92L variant glutamate dehydrogenases by Escherichia coli
- E. coli cells expressing bST protein are a good experimental system by which to test the effectiveness of norleucine degrading enzymes for reducing or eliminating norleucine incorporation into protein.
- GDH E. coli glutamate dehydrogenase
- pXT757 Both the wild-type and K92L variant glutamate dehydrogenase encoding genes were separately cloned into the bST expression vector pXT757.
- the construction and structural features of pXT757 are disclosed in WO 00/060103 and WO 02/051238 (which are each incorporated herein by reference).
- the plasmid pXT757 is based on the well-known vector pBR322, and includes an inducible promoter driving the expression of the bovine somatotropin gene. Downstream of the bovine somatotropin gene is the constitutive lacUN5 promoter.
- the wild-type and K92L variant glutamate dehydrogenase genes were cloned into pXT757 downstream of the lacUN5 promoter so that the glutamate dehydrogenase proteins would be constitutively expressed (i.e. both before and after induction of bovine somatotropin synthesis).
- bST was expressed from an inducible promoter such as the cpex-20 promoter disclosed in WO 00/060103 and WO 02/051238).
- the new plasmid with the wild-type E. coli glutamate dehydrogenase gene was designated pXT814, and the new plasmid with the K92L variant of the E. coli glutamate dehydrogenase gene was designated pXT815.
- ATCC number refers to the American-Type Culture Collection on-line catalog number for the species.
- Such enzymes may include members of a super-family of enzymes related to E. coli glutamate dehydrogenase and the proteins listed in
- this protein super-family includes glutamate dehydrogenases, leucine dehydrogenases, valine dehydrogenases, phenylalanine dehydrogenases, glutamate/leucine/phenylalanine/valine dehydrogenases, and opine dehydrogenases.
- Example 2 Co-expression of bovine somatotropin with norleucine (and other non-standard amino acid) degrading proteins
- LBB427 is a derivative of the common K-12 strain, W3110, differing only in that LBB427 has fliuA gene knockout mutation.
- the conditions for the growth and induction of such bST expressing strains are disclosed in WO 00/060103. Briefly, the transformed strains were grown on minimal medium (i.e.
- the assay employs a high performance liquid chromatographic (HPLC) column run under conditions that resolve norleucine-free bovine somatotropin and norleucine-containing bovine somatotropin into separate peaks, which can then easily be quantified.
- HPLC high performance liquid chromatographic
- the norleucine-containing bovine somatotropin was separated from the bulk of bovine somatotropin with a Perkin-Elmer Series 4 HPLC using a Nydac C-18 column.
- the chromatographic conditions were a flow rate of 2 ml/minute with constant 40 mM trifluoroacetic acid, followed by a gradient of 54-60% acetonitrile over 24 minutes, followed by a gradient of 60-75% acetonitrile over 6 minutes.
- the strain transformed with pXT757 was used as a control (i.e. one not co-expressing any norleucine (or other non-standard amino acid) degrading enzyme.
- the resulting percentages of bST containing norleucine were as shown in Table 5.
- leucine dehydrogenase gene products from Bacillus cereus (ATCC 14579), Shewanella oneidensis (ATCC 700550) and the glutamate/leucine/phenylalanine/valine dehydrogenase gene product from Nitrosomonas europaea (ATCC 19718) each reduce the percentage of protein containing norleucine to substantially zero (i.e., below detectable limits).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09169352A EP2119794A1 (fr) | 2003-09-25 | 2004-09-23 | Procédés permettant d'empêcher l'incorporation d'acides aminés non standard dans des protéines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50580703P | 2003-09-25 | 2003-09-25 | |
PCT/US2004/031224 WO2005038017A2 (fr) | 2003-09-25 | 2004-09-23 | Procedes permettant d'empecher l'incorporation d'acides amines non standard dans des proteines |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09169352A Division EP2119794A1 (fr) | 2003-09-25 | 2004-09-23 | Procédés permettant d'empêcher l'incorporation d'acides aminés non standard dans des protéines |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1702074A2 true EP1702074A2 (fr) | 2006-09-20 |
EP1702074B1 EP1702074B1 (fr) | 2009-11-11 |
Family
ID=34465075
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09169352A Withdrawn EP2119794A1 (fr) | 2003-09-25 | 2004-09-23 | Procédés permettant d'empêcher l'incorporation d'acides aminés non standard dans des protéines |
EP04817242A Active EP1702074B1 (fr) | 2003-09-25 | 2004-09-23 | Procedes permettant d'empecher l'incorporation d'acides amines non standard dans des proteines |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09169352A Withdrawn EP2119794A1 (fr) | 2003-09-25 | 2004-09-23 | Procédés permettant d'empêcher l'incorporation d'acides aminés non standard dans des protéines |
Country Status (8)
Country | Link |
---|---|
US (1) | US8603781B2 (fr) |
EP (2) | EP2119794A1 (fr) |
KR (1) | KR101234439B1 (fr) |
AT (1) | ATE448321T1 (fr) |
AU (1) | AU2004282492B2 (fr) |
CA (1) | CA2539996C (fr) |
DE (1) | DE602004024122D1 (fr) |
WO (1) | WO2005038017A2 (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100463263B1 (ko) * | 2001-10-09 | 2004-12-23 | 경희대학교 산학협력단 | 골길이 성장 촉진 효과를 가지는 가시오가피 추출물 및 이를 함유하는 약학적 제제 |
EP1996697A2 (fr) * | 2006-03-07 | 2008-12-03 | Novartis AG | Prevention du defaut d'incorporation de la norvaline et de la norleucine dans des proteines recombinantes |
WO2011106696A2 (fr) | 2010-02-26 | 2011-09-01 | The Regents Of The University Of California | Compositions et procédés pour la production de l-homoalanine |
US8974843B2 (en) * | 2010-10-01 | 2015-03-10 | Ronald E. Rosedale | mTOR pathway optimized nutritional compositions |
US9193957B2 (en) | 2012-05-11 | 2015-11-24 | Codexis, Inc. | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds |
EP2898086B1 (fr) | 2012-09-19 | 2018-11-14 | F.Hoffmann-La Roche Ag | Méthodes et compositions pour la prévention d'une mauvaise incorporation de norleucine dans des protéines |
EP3201326B1 (fr) | 2014-10-03 | 2020-03-04 | Metabolic Explorer | Déshydrogénase glutamate mutante pour la conversion de l'homosérine en 4-hydroxy-2-ketobutyrate |
EP3081639A1 (fr) * | 2015-04-14 | 2016-10-19 | Evonik Degussa GmbH | Production d'un acide aminé acylé |
US20190211377A1 (en) * | 2016-12-22 | 2019-07-11 | Roche Molecular Systems, Inc. | Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile |
WO2020126700A1 (fr) * | 2018-12-20 | 2020-06-25 | Sanofi-Aventis Deutschland Gmbh | Procédé de réduction de l'incorporation erronée d'acides aminés à chaîne ramifiée non canonique |
WO2024079114A1 (fr) | 2022-10-11 | 2024-04-18 | UCB Biopharma SRL | Procédé de production de protéines recombinantes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789234A (en) * | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
US5599690A (en) | 1988-02-01 | 1997-02-04 | Amgen Inc. | Control of norleucine incorporation into recombinant proteins |
US5698418A (en) * | 1988-02-17 | 1997-12-16 | Pharmacia & Upjohn Company | Fermentation media and methods for controlling norleucine in polypeptides |
ATE152176T1 (de) | 1988-02-17 | 1997-05-15 | Upjohn Co | Verfahren zum regeln des norleucingehalts in polypeptiden |
EP0724629A1 (fr) * | 1993-10-18 | 1996-08-07 | Degussa Aktiengesellschaft | Procede de modification controlee d'enzymes, enzymes modifiees et utilisation |
US5932439A (en) * | 1995-11-13 | 1999-08-03 | Monsanto Comapny | Escherichia coli K-12 strains for production of recombinant proteins |
WO2000060103A2 (fr) | 1999-04-01 | 2000-10-12 | Monsanto Technology Llc | Construction d'adn destinee a reguler l'expression d'une sequence codant un polypeptide dans une cellule hote bacterienne transformee |
KR100847386B1 (ko) | 2000-12-26 | 2008-07-18 | 몬산토 테크놀로지 엘엘씨 | 소마토트로핀의 발현을 위한 재조합 dna 벡터 |
CA2741649A1 (fr) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Antagonistes des recepteurs de l'orexine a base de pyridazine-carboxamide |
-
2004
- 2004-09-23 KR KR1020067007359A patent/KR101234439B1/ko active IP Right Grant
- 2004-09-23 EP EP09169352A patent/EP2119794A1/fr not_active Withdrawn
- 2004-09-23 WO PCT/US2004/031224 patent/WO2005038017A2/fr active Application Filing
- 2004-09-23 AT AT04817242T patent/ATE448321T1/de active
- 2004-09-23 AU AU2004282492A patent/AU2004282492B2/en active Active
- 2004-09-23 DE DE602004024122T patent/DE602004024122D1/de active Active
- 2004-09-23 EP EP04817242A patent/EP1702074B1/fr active Active
- 2004-09-23 US US10/572,711 patent/US8603781B2/en active Active
- 2004-09-23 CA CA2539996A patent/CA2539996C/fr active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2005038017A2 * |
Also Published As
Publication number | Publication date |
---|---|
ATE448321T1 (de) | 2009-11-15 |
AU2004282492A1 (en) | 2005-04-28 |
US8603781B2 (en) | 2013-12-10 |
CA2539996A1 (fr) | 2005-04-28 |
AU2004282492B2 (en) | 2011-02-10 |
WO2005038017A2 (fr) | 2005-04-28 |
CA2539996C (fr) | 2013-11-26 |
WO2005038017A3 (fr) | 2005-08-11 |
KR20070030165A (ko) | 2007-03-15 |
DE602004024122D1 (de) | 2009-12-24 |
KR101234439B1 (ko) | 2013-02-18 |
EP2119794A1 (fr) | 2009-11-18 |
WO2005038017A8 (fr) | 2005-12-15 |
US20070009995A1 (en) | 2007-01-11 |
EP1702074B1 (fr) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0669980B1 (fr) | Procede de regulation de la production de polypeptides dans des bacteries | |
RU2094439C1 (ru) | Рекомбинантный полипептид pgh(a) с n-концевым аланином | |
EP1733039B1 (fr) | Ameliorations apportees a une cellule hote bacterienne destinee a l'expression directe de peptides | |
AU731758B2 (en) | Method for secretory production of human growth hormone | |
CA2433485A1 (fr) | Methode de production par fermentation d'aminoacides et de derives d'aminoacides de la famille des phosphoglycerates | |
EP1702074B1 (fr) | Procedes permettant d'empecher l'incorporation d'acides amines non standard dans des proteines | |
EP0992588B1 (fr) | Plasmide d'expression pour DsbA/DsbB/DsbC/DsbD | |
JP2016202182A (ja) | cycA遺伝子を過剰発現した腸内細菌科の細菌を用いたL−イソロイシンの製造方法 | |
AU692728B2 (en) | Method for secretory production of protein | |
JP2001008697A (ja) | E.コリでの非融合タンパク質の調製方法 | |
KR100484602B1 (ko) | 박테리아 발현 시스템에서 포밀-메티오닌 펩타이드의 탈포밀화 | |
US5698418A (en) | Fermentation media and methods for controlling norleucine in polypeptides | |
US9487576B2 (en) | Method for reduction of 1->2 reading frame shifts | |
Chakraborty et al. | Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in streptomyces avermitilis | |
US20150064746A1 (en) | Method for reduction of 1->3 reading frame shifts | |
Chakraborty et al. | Overexpression and purification of recombinant eel calcitonin and its phylogenetic analysis | |
EP0737752A2 (fr) | Milieu de fermentation et méthode pour contrÔler l'incorporation de norleucine en des polypeptides | |
Stillman | Bogosian et al. | |
EP2912173B1 (fr) | Procédé de préparation et purification de la oncostatin m humaine recombinante | |
EP3856918A1 (fr) | Procédé de production de l-méthionine à l'aide d'une bactérie | |
WO2011103325A1 (fr) | Hgh et procédés de préparation de hgh | |
JP2002291476A (ja) | ヒト上皮細胞増殖因子の製造法、および、該方法に使用する形質転換コリネ型細菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060404 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20070206 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 602004024122 Country of ref document: DE Date of ref document: 20091224 Kind code of ref document: P |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100222 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100311 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20100812 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100212 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20100923 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20110531 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602004024122 Country of ref document: DE Effective date: 20110401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110401 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100923 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100512 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20100923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091111 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20230825 Year of fee payment: 20 |